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Many diseases of the eye such as retinoblastoma, diabetic retinopathy, and retinopathy of prematurity are associated with blood–retinal
barrier (BRB) dysfunction. Identifying the factors that contribute to BRB formation during human eye development and maintenance
could provide insights into such diseases. Here we show that A-kinase anchor protein 12 (AKAP12) induces BRB formation by increasing
angiopoietin-1 and decreasing vascular endothelial growth factor (VEGF) levels in astrocytes. We reveal that AKAP12 downregulates the
level of hypoxia-inducible factor-1 (HIF-1) protein by enhancing the interaction of HIF-1 with pVHL (von Hippel-Lindau tumor
suppressor protein) and PHD2 (prolyl hydroxylase 2). Conditioned media from AKAP12-overexpressing astrocytes induced barriergen-
esis by upregulating the expression of tight junction proteins in human retina microvascular endothelial cells (HRMECs). Compared with
the retina during BRB maturation, AKAP12 expression in retinoblastoma patient tissue was markedly reduced whereas that of VEGF was
increased. These findings suggest that AKAP12 may induce BRB formation through antiangiogenesis and barriergenesis in the develop-
ing human eye and that defects in this mechanism can lead to a loss of tight junction proteins and contribute to the development of retinal
pathologies such as retinoblastoma.
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Introduction
The blood–retinal barrier (BRB) is a selective barrier of the eye
composed of well differentiated microvessels. It plays an essential
role in protecting neural tissues from toxic materials and in main-
taining vision and neural function in the retina. The inner mature
BRB is a complex system composed of highly specialized micro-
vascular endothelial cells embedded in a basement membrane
and surrounded by astrocytic end feet. In many in vitro models,
astrocytes can induce barrier-like features when cocultured with
cerebral brain endothelial cells (Stanness et al., 1996; Lee et al.,
2003). A typical BRB-defect eye disease, retinoblastoma, is the
most common intraocular malignant tumor in children. Retino-
blastoma arises in the retina and is characterized by a lack of
intermediate filaments (Kivela et al., 1986), leaky vessels, and
high levels of vascular endothelial growth factor (VEGF). The
expression of VEGF is mainly regulated by hypoxia-inducible
factor-1 (HIF-1) (Ikeda et al., 1995; Ema et al., 1997; Maxwell
et al., 1997), which is the most important transcriptional factor in
hypoxia-induced angiogenesis (Semenza, 2003).
HIF-1 is composed of two subunits, an oxygen-sensitive
HIF-1 subunit and oxygen-insensitive HIF-1 subunit (Wang
et al., 1995). HIF-1 is stable under hypoxia, whereas it is unsta-
ble under normoxia. In normoxic conditions, the HIF-1 sub-
unit is rapidly degraded via the von Hippel-Lindau tumor sup-
pressor protein (pVHL)-mediated ubiquitin-proteasome
pathway (Salceda and Caro, 1997; Maxwell et al., 1999). The
association of pVHL and HIF-1 is triggered by prolyl hydroxy-
lation within a polypeptide segment known as the oxygen-
dependent degradation domain through the function of specific
HIF-prolyl hydroxylases (PHDs) (Ivan et al., 2001; Jaakkola et al.,
2001). In mammalian cells, three isoforms, PHD1, PHD2, and
PHD3, have been identified and shown to hydroxylate in vitro the
key proline residues of HIF-1 (Epstein et al., 2001).
A-kinase anchor protein 12 (AKAP12) is a putative tumor
suppressor that associates with protein kinase A (PKA) and pro-
tein kinase C (PKC) and serves as a scaffolding protein in signal
transduction (Gelman et al., 2000; Gelman, 2002). AKAP12 ex-
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pression is strongly suppressed in a variety of cancers (Xia et al.,
2001; Liu et al., 2006). Src-suppressed C-kinase substrate
(SSeCKS), the rodent ortholog of human AKAP12, is important
for mouse brain homeostasis and regulating the formation of the
blood– brain barrier (Lee et al., 2003). A recent report showed
that SSeCKS/AKAP12 attenuates expression of angiogenic genes
by suppressing Src-induced oncogenesis (Liu et al., 2006). How-
ever, it is not clear whether AKAP12 participates in antiangiogen-
esis and barriergenesis in the human retina. Moreover, the mech-
anism of barrier failure in the human eye is not well understood.
In this study, we identified AKAP12 as a BRB-inducing factor in
the developing human eye and provide evidence that aberrantly
low expression of AKAP12 in retinoblastoma may lead to BRB
dysfunction in this disease.
Materials and Methods
Tissue preparation and immunohistochemistry. A panel of human fetal
eyes ranging every week from 18 to 40 weeks and five primarily enucle-
ated eyes from retinoblastoma patients were used in this study. All sam-
ples were obtained with informed consent, institutional review board
approval, and in accordance with the tenets of the Declaration of Hel-
sinki. Fetal eyeballs were obtained from fetal autopsies at the Seoul Na-
tional University Children’s Hospital. The specimens selected were from
fetuses that had no history of ophthalmologic congenital anomalies. Ges-
tational age was determined from the last menstrual period of the mother
and fetal measurements. Primarily enucleated eyeballs from patients di-
agnosed with retinoblastoma were obtained
from the Seoul National University Children’s
Hospital. After nucleation, the eyeballs were
fixed by immersion in Carnoy’s solution for 2 h
at room temperature. Each specimen was then
dehydrated through a series of graded ethanol
solutions and embedded in paraffin using stan-
dard techniques. Paraffin-embedded eyes were
sectioned into 4 m sections, and sections were
mounted on slides coated with 0.5% Elmer’s
glue for immunohistochemistry. Immunohis-
tochemistry was performed using an Inno-
Genex (San Ramon, CA) immunohistochemis-
try kit. For quantitative analysis of
immunostaining, Image-Pro Plus (Media
Cybernetics, Bethesda, MD) was used.
Immunofluorescence staining. Cryosections
were incubated with the indicated primary an-
tibodies, followed by FITC-conjugated IgG
and tetramethylrhodamine isothiocyanate-
conjugated IgG (Jackson ImmunoResearch,
West Grove, PA) as secondary antibodies. Flu-
orescence immunostaining was evaluated us-
ing a confocal microscope (Bio-Rad, Hercules,
CA). Human astrocyte cells were incubated
overnight at 4°C with the indicated primary
antibodies, followed by incubation with Alexa
Fluor antibodies. Nuclei were stained using
propidium iodide (Invitrogen, San Diego, CA).
Images were obtained with an Axiovert M200
microscope (Zeiss, Oberkochen, Germany)
and analyzed using Image-Pro Plus (Media
Cybernetics).
Cell culture. Primary human brain astrocyte
cells and dissociated normal human brain cor-
tex tissue were purchased from the Applied Cell
Biology Research Institute (Kirkland, WA).
The CTX-TNA2 cell line, an established astro-
cytic cell line from the neonatal Sprague Daw-
ley rat cerebral cortex, was purchased from the
American Type Culture Collection (Manassas,
VA). Primary human brain astrocyte cells,
CTX-TNA2 cells, 786-O renal clear cell carcinoma cells, and HT1080
cells were cultured in DMEM supplemented with 10% FBS (Invitrogen)
and antibiotics. Human retina microvascular endothelial cells
(HRMECs) were purchased from the Applied Cell Biology Research In-
stitute and grown on attachment factor-coated plates in complete me-
dium (Cell Systems, Kirkland, WA) or in M199 medium supplemented
with 20% FBS, 3 ng/ml basic FGF (Millipore, Bedford, MA), and 10 U/ml
heparin (Sigma, St. Louis, MO). For the analysis of HIF-1 stability in
786-O renal clear cell carcinoma cells, cells were transfected with a plas-
mid encoding myc-pVHL and selected using G418 (Invitrogen; or BRL,
Bethesda, MD). For hypoxia experiments, astrocytes were incubated in a
hypoxic chamber (Forma Scientific, San Bruno, CA) that maintained the
cells under low oxygen tension (5% CO2 with 1% O2, balanced with N2).
Luciferase assay. Astrocytes were transfected with a plasmid for
Akap12, the hypoxia-response element (HRE) luciferase reporter vector,
or the VEGF promoter vector (pGL3-mVEGF), pBOS-hHIF and pCMV-
-gal. Luciferase assays were performed using the Luciferase Assay Sys-
tem (Promega, Madison, WI), and analyzed using a luminometer
(Turner Designs, Sunnyvale, CA). Luciferase-generated light units were
normalized to -galactosidase activity.
Western blot analysis. Cellular protein from transfected astrocytes or
conditioned medium (CM)-treated HRMECs and secreted proteins in
CM were analyzed by Western blot. Western blot analysis was performed
as described previously (Moon et al., 2004). We used antibodies specific
for AKAP12 (a gift from Dr. I. H. Gelman, Roswell Park Cancer Institute,
Buffalo, NY; or Santa Cruz Biotechnology, Santa Cruz, CA); HIF-1
(Novus Biologicals, Littleton, CO; or BD Pharmingen, San Diego, CA);
Figure 1. Immunohistochemical analysis of AKAP12, vWF, GFAP, Ang1, VEGF, and tight junction proteins in the developing
human retina. Human fetal retinal sections were immunostained with antibodies to AKAP12, vWF, GFAP, Ang1, claudin-1, occlu-
din, and VEGF (red). Nuclei were counterstained with hematoxylin and are seen in blue. The negative control was immunostained
with normal rabbit IgG. GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. Scale bar, 50 m.
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VEGF (Santa Cruz Biotechnology); zonula oc-
cludens 1 (ZO-1), claudin-3, and claudin-5
(Zymed, San Francisco, CA); claudin-1
(Zymed; or Abcam, Cambridge, UK); occludin
(Santa Cruz Biotechnology or Zymed);
angiopoietin-1 (Ang1; R & D Systems, Minne-
apolis, MN; or Santa Cruz Biotechnology);
pVHL (BD PharMingen); PHD2 (Novus Bio-
logicals); -actin (Sigma); -tubulin (Bio-
Genex, San Ramon, CA). Recombinant
VEGF165 was purchased from R & D Systems,
and COMP-Ang1 was a generous gift from Dr.
G. Y. Koh (Korea Advanced Institute of Science
and Technology, Daejeon, Korea). L-mimosine
(Mim) and ethyl 3,4-dihydroxybenzoate
(DHB) were purchased from Sigma and used at
a 300 M concentration. MG132, a proteasome
inhibitor, was purchased from Calbiochem (La
Jolla, CA). Ponceau S solution was purchased
from Sigma.
Immunoprecipitation. Cellular protein (300
g) from transfected astrocytes was incubated
with the indicated antibodies and protein A or
G Sepharose in TEG buffer (20 mM Tris-Cl,
pH 7.4, 1 mM EDTA, 10% glycerol, and 1 mM
dithiothreitol containing 150 mM NaCl and
0.1% Triton X-100) at 4°C for 16 h with con-
stant rotation. Sepharose pellets were col-
lected by centrifugation and washed three
times with supplemented TEG buffer. Immu-
noprecipitates were analyzed by SDS-PAGE,
followed by Western blot using the indicated
antibodies.
Transient transfection and CM preparation.
The full-length rat Akap12 cDNA was sub-
cloned into the pcDNA3. Transient transfec-
tions were performed using Lipofectamine Plus
reagent (Invitrogen). For preparation of CM
for Western blot analysis, FBS-free medium
from transfected cells was collected and con-
centrated through an Ultra-4 filter device (Mil-
lipore, Beverly, MA). We also used trichloro-
acetic acid precipitation, as described by
Sambrook and Russel (2001). For preparation
of CM for treating HRMECs, medium from
transfected astrocytes was changed into M199
medium containing 1% FBS for 24 h, collected
and filtered through a 0.22 m pore size mem-
brane (Millipore), and then concentrated four
times using centrifugal filters (Millipore).
Permeability assay. Permeability across the
endothelial cell monolayer was measured by
using type I collagen-coated transwell units
(6.5 mm diameter, 3.0 m pore size polycar-
bonate filter; Corning, Corning, NY; or
Costar, Cambridge, MA). After HRMECs become confluent, CM was
treated for 24 h. Permeability was measured by adding 0.1 mg of
Rhodamine B isothiocyanate (RITC)-labeled dextran (molecular
weight, 10,000) per milliliter to the upper chamber. After incuba-
tion for 15 min, 100 l of sample from the lower compartment was
diluted with 100 l of PBS and measured for fluorescence at 635 nm
when excited at 540 nm with a spectrophotometer (Tecan Spec-
traFluor; Tecan Durham, NC).
RNA interference. Astrocytes were grown to 80% confluence, and
small interfering RNAs (siRNAs) (50 M) were transfected into the
cells using Lipofectamine Plus or Lipofectamine2000 reagent (In-
vitrogen). All transfections were performed according to the manu-
facturer’s instructions. siRNAs and the control nonsilencing RNAs
were designed by Dharmacon (Lafayette, CO). The human Akap12
target sequence used was as follows: 5-AGACGGATGTAG-
TGTTGAA-3. The human PHD2 target sequence used was as follows:
5-CTTCAGATTCGGTCGGTAAAG-3. The human HIF-1 target
sequence used was as follows: 5-CTGGACACAGTGTGTTTGA-3.
Reverse transcription PCR. Total RNA was isolated from the indicated
cells using Trizol reagent (Invitrogen). Reverse-transcription (RT)-PCR
analysis was performed as described previously (Lee et al., 2001a). The
following sets of primers were used: rat Akap12, 5-GCCAGTCC-
TGACACTTG-3, 5-TGAGCCCATGCCTCCAGAA-3; VEGF, 5-
GAGAATTCGGCCTCCGAAACCATGAACTTTCTGT-3 (forward)
and 5-GAGCATGCCCTCCTGCCCGGCTCACCGC-3 (reverse);
human HIF-1 5-AGTCGGACAGCCTCAC-3 (forward) and 5-
TGCTGCCTTGTATAGGA-3 (reverse); human Ang1, 5-GAAGGG-
AACCGAGCCTATTC-3 (forward) and 5-GGGCACATTTGCA-
Figure 2. Immunohistochemical analysis in the developing human retina. A, Immunoreactivity of the indicated factors was
quantified using Image-Pro Plus and is presented relative to the area with the highest staining intensity at 27 weeks (AKAP12,
GFAP, Ang1, claudin-1, ZO-2, and occludin) or at 24 weeks (VEGF and vWF). At least three different tissues were used for each stage
from 18 to 40 weeks. B, Immunohistochemical analysis of the expression of AKAP12, GFAP, Ang1, VEGF, vWF, and the tight
junction proteins claudin-1, ZO-2, and occludin. The negative control was immunostained with normal rabbit IgG. C, Double
immunofluorescence staining for AKAP12 (red) and GFAP (green) at 34 weeks of fetal retinal tissue. Colocalization of the two
proteins is seen as yellow fluorescence. Scale bars, 50 m.
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CATACAG-3 (reverse). PCR products were analyzed on 1.2% agarose
gels and the gels were digitally imaged.
Data analysis and statistics. Quantification of band intensity was ana-
lyzed using ImageJ (http://rsb.info.nih.gov/ij/) and normalized to the
density of the -actin or ponceau staining band. All data are presented as
mean  SD changed into relative percentage. The highest intensity of
each protein level was set to 100%. Statistical comparisons between
groups were done using Student’s test. p  0.05 was considered statisti-
cally significant.
Results
AKAP12 immunoreactivity in vivo during human
eye development
To examine the changes in AKAP12 immunoreactivity in vivo
during human eye development, we used immunohistochemis-
try to quantitatively analyze immunostained retinas every week
from 18 to 40 weeks of development. AKAP12 expression was not
detected before 22 weeks but was clearly detectable from 22 to 40
weeks. The highest AKAP12 expression was detected during
26 –34 weeks, which is the period of vascular maturation in the
eye (Figs. 1, 2A). Moreover, AKAP12-positive immunostaining
was present surrounding blood vessels in the tissues. Immunopo-
sitive staining of von Willebrand factor (vWF), a vessel marker,
was detected at 24 weeks and maintained throughout human
retinal development. The staining pattern of glial fibrillary acidic
protein (GFAP), an astrocyte-specific marker, and Ang1 also co-
incided spatiotemporally with that of AKAP12 (Figs. 1, 2A).
Ang1 acts as a key factor in vessel matura-
tion by increasing the expression of tight
junction proteins in endothelial cells (Lee
et al., 2003; Hori et al., 2004). We found
that the expression pattern of tight junc-
tion proteins such as claudin-1, ZO-2, and
occludin was similar to that of Ang1 and
AKAP12 during human retinal develop-
ment (Figs. 1, 2A). Furthermore, we de-
termined VEGF expression at the same
stages to assess retina angiogenesis and the
oxygen state (Lee et al., 2001b; Sandercoe
et al., 2003; Werdich et al., 2004). VEGF
immunoreactivity increased during the
early stages of fetal eye development,
peaked at 24 weeks during active angio-
genesis, and declined thereafter (Figs. 1,
2A). Thus, the expression of VEGF varied
inversely with that of AKAP12, because
the VEGF-stained area remarkably de-
creased during BRB maturation, whereas
the areas stained by AKAP12 increased
markedly.
To identify the locations of AKAP12,
Ang1, and tight junction proteins, we ex-
amined their pattern of expression in tis-
sues surrounding retinal vessels at 34
weeks. AKAP12 appeared to localize in as-
trocytes, which were identified by GFAP-
positive immunostaining (Fig. 2B). More-
over, coexpression analysis at 34 weeks in
retina tissue revealed that AKAP12 immu-
nofluorescence overlapped with that of
GFAP (Fig. 2C), indicating that AKAP12 is
expressed in astrocytes in the fetal retina.
As shown in Figure 2B, Ang1 expression
was detected in perivascular regions,
whereas VEGF expression was not de-
tected. When vessels were immunostained for vWF, we found
that immunopositive staining of claudin-1, ZO-2, and occludin
coincided spatiotemporally with that of vWF (Fig. 2B). These
staining patterns indicate that AKAP12-expressing astrocytes lo-
calize close to retinal vessels and that AKAP12 may induce the
formation of tight junctions in endothelial cells, thus stabilizing
the BRB structure.
AKAP12 immunoreactivity in retinoblastoma tissues
To extend our findings to human retinal pathology, we con-
ducted fluorescein angiograms of retinoblastoma tissues and ex-
amined expression of AKAP12, GFAP, and tight junction pro-
teins in the tumor and in the surrounding tissues (Fig. 3). The
angiograms showed leakage of fluorescein from the tumor vessels
(data not shown). Interestingly, AKAP12- and GFAP-positive
immunostaining was restricted to areas of the retina outside of
the tumor and was not detected within the tumor (Fig. 3A), al-
though many blood vessels were distributed all over the tumor, as
revealed by strong vWF-positive staining (Fig. 3B). AKAP12 im-
munoreactivity in retinoblastoma tissue coincided with that of
GFAP, with both exhibiting weak and irregular distribution pat-
terns along the vessels of the retina (Fig. 3). In contrast, VEGF
expression was increased both within the region of the tumor and
in the retinal region outside of the tumor. HIF-1 was weakly
detected in the transformed region from retina to tumor and
Figure 3. Immunohistochemical analysis in the retinoblastoma tissues. A, Immunohistochemical analysis of AKAP12 and GFAP
in retinoblastoma tissue. Retina (RE), Area of the retina outside of the tumor; retinoblastoma (RB), tumor region. B, Immunohis-
tochemical analysis of vWF, AKAP12, GFAP, VEGF, HIF-1, Ang1, claudin-1, and occludin expression in the RE (left) and RB (right)
of retinoblastoma tissues. Scale bars, 50 m.
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strongly detected in the tumor region (Fig. 3B). However, Ang1,
claudin-1, and occludin expression was completely absent in the
retinoblastoma tissue and in the surrounding retina (Fig. 3B),
and the level of ZO-2 was not detected in retinoblastoma tissues
(data not shown). These results suggest that reduced expression
of AKAP12 and Ang1 and increased expression of VEGF and
HIF-1 are closely related to the disappearance of tight junctions
and the leakage of retinoblastoma blood vessels.
AKAP12 regulates the expression of Ang1 and VEGF
The natural generation of hypoxia in the developing retina in-
duces key events in the formation of blood vessels (West et al.,
2005). Exposure of astrocytes to the resulting elevated oxygen
levels (reoxygenation) may contribute to the maturation of the
retinal vessels. AKAP12 level was decreased during hypoxia and
increased during reoxygenation in human astrocytes (Fig. 4A).
Also during reoxygenation, the level of Ang1 and VEGF in CM
was upregulated and downregulated, respectively, compared
with that of the hypoxic condition (Fig. 4A), indicating that there
is a counteracting mechanism for the regulation of Ang1 and
VEGF that may be influenced by AKAP12. To investigate the role
of AKAP12 in BRB differentiation, we transfected an siRNA tar-
geting Akap12 (siAkap12) into human astrocytes. Inhibition of
AKAP12 expression by siAkap12 resulted in a decrease in the
expression of Ang1 and an increase in the level of VEGF in CM
(Fig. 4B). Transfection of Akap12 into human astrocytes in-
creased Ang1 levels in CM under hypoxic conditions (Fig. 4C).
These results show that AKAP12 influences the secretion of an
angiogenic factor, VEGF, and vessel remodeling factor, Ang1, in
response to oxygen tension.
Ang1 mediates effect of AKAP12 on tight junction proteins
To investigate whether AKAP12 induces inner BRB formation,
we examined the effect of CM from Akap12-transfected astro-
cytes (AKAP-CM) on the expression of tight junction proteins,
which are important in maintaining barrier function (Morcos et
al., 2001; Engelhardt, 2003; Abbott et al., 2006) in HRMECs.
AKAP-CM strongly increased the expression of ZO-1, ZO-2,
claudin-1, claudin-3, claudin-5, and occludin in HRMECs (Fig.
5A). These effects were blocked when the AKAP12-CM was pre-
treated with an anti-Ang1 antibody. Using the passage of RITC-
dextran through monolayers of HRMECs as a measure of perme-
ability, we found that AKAP-CM significantly reduced vascular
permeability, whereas Ang1-neutralized AKAP-CM did not (Fig.
5B). These results indicate that the expression of AKAP12 in
astrocytes may induce the barrier function between endothelial
cells in part through Ang1. To explore the roles of Ang1 and
VEGF in BRB formation, we treated HRMECs with recombinant
VEGF165 and a chimeric form of Ang1 in which the N-terminal
portion of Ang1 was replaced with the short-coiled coil domain
of cartilage oligomeric matrix protein (COMP-Ang1). COMP-
Ang1 is soluble and more potent than native Ang1 in phosphor-
ylating the Tie2 receptor and Akt in endothelial cells (Cho et al.,
2004). COMP-Ang1 treatment of HRMECs induced a greater
increase in the expression of ZO-1 and ZO-2, whereas VEGF
treatment decreased the levels of ZO-1 and ZO-2 (Fig. 5C). Be-
cause the inhibition of AKAP12 expression by siAkap12 resulted
in a decrease of Ang1 and an increase of VEGF in CM (Fig. 4B),
we investigated whether siAkap12-transfected CM (siAkap-CM)
from astrocytes influences the distribution of ZO-1, ZO-2, and
claudin-1 in HRMECs. ZO-1, ZO-2, and claudin-1 immunoflu-
orescence incubated with siAkap-CM was significantly de-
creased, exhibiting weak and discontinuous distribution patterns
along the cell– cell contact in HRMECs (Fig. 5D). The expression
of claudin-5 and occludin, the main structural transmembrane
component of tight junction proteins (Furuse et al., 1994; Nitta et
al., 2003), was also significantly reduced (Fig. 5D) and the vascu-
lar permeability was remarkably ( p  0.01) increased at the same
conditions (data not shown). These results suggest that reciprocal
regulation of the levels of Ang1 and VEGF by AKAP12 may play a
major role in inducing vessel tightness during BRB maturation.
Next, we investigated whether HIF-1 is involved in the regula-
tion of Ang1 expression because the expression of Ang1 was
tightly regulated by oxygen tension in astrocytes (Fig. 4A). To
examine the effect of HIF-1 on Ang1 expression, siRNA target-
ing HIF-1 (siHIF-1) was transfected into human astrocytes.
Figure 4. AKAP12 differentially regulates the expression of Ang1 and VEGF. A, Human as-
trocytes were exposed to normoxia (N), 24 h of hypoxia (24H), or 24 h of hypoxia followed by 3 h
of reoxygenation (3R). AKAP12 in cell lysates and Ang1 and VEGF in CM were analyzed by
Western blot under the indicated levels of oxygen tension. The quantification of the immuno-
blot from three independent experiments is shown on the right. The expression of AKAP12 and
Ang1 under normoxia was set to 100% and the VEGF expression under hypoxia was set to 100%.
*p  0.05 compared with normoxic and reoxygenation conditions; #p  0.01 compared with
normoxic and reoxygenation conditions. B, Human astrocytes were transfected with siAkap12,
incubated for 12 h, and then exposed to 24 h of normoxia or hypoxia. The quantification of the
immunoblot from four independent experiments is shown on the right. Ang1 expression was
set to 100% in the control under normoxia, and VEGF expression was set to 100% in siAkap12-
transfected hypoxic condition. **p  0.001 compared with control in normoxic condition;
*p  0.05 compared with control in normoxic condition; #p  0.05 compared with control in
hypoxic condition. C, Rat Akap12 was transfected into human astrocytes, incubated for 12 h,
then exposed to 24 h of normoxia or hypoxia. Levels of transfected AKAP12 protein (t-AKAP12)
in whole-cell lysate and Ang1 in CM were analyzed by Western blot. The quantification of the
immunoblot from three independent experiments is shown on the right. The expression under
normoxia was set to 100%. *p  0.05 compared with mock-transfected control in hypoxic
condition. -actin and Ponceau red staining served as the controls for total protein levels.
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We found that siHIF-1 increased the level of Ang1 in CM from
transfected cells and decreased the level of VEGF (Fig. 6A). In
addition, the level of Ang1 mRNA was also upregulated, whereas
VEGF mRNA was downregulated in siHIF-1-transfected cells
(Fig. 6B). These results suggest that secretion of Ang1 and VEGF
induced by astrocytic AKAP12 is mediated in part by HIF-1.
Negative regulation of HIF-1 stability by AKAP12
AKAP12 and HIF-1 were reciprocally regulated by oxygen ten-
sion (Fig. 7A). Therefore, we examined the effect of AKAP12 on
HIF-1 and found that overexpression of AKAP12 in human
astrocytes significantly decreased the level of HIF-1 protein in
cell lysates (Fig. 7B) but did not decrease HIF-1 mRNA level
(Fig. 7C). We also found that transfection with siAkap12 mark-
edly induced HIF-1 level, as assessed by Western blot, under
both normoxic and hypoxic conditions (Fig. 7D). Moreover, an
enhanced level of HIF-1 after transfection of siAkap12 was
clearly detected in the nucleus by immunocytochemistry (Fig.
7E). Thus, inhibition of AKAP12 through siAkap12 transfection
significantly increased the level of HIF-1 protein in astrocytes,
whereas overexpression of AKAP12 diminished HIF-1 protein
level.
Inhibition of HIF-1- and VEGF-mediated transactivation
by AKAP12
Next, we performed a luciferase reporter assay and found that
overexpression of AKAP12 inhibited the transcriptional activity
of HIF-1 under hypoxic condition, suggesting that AKAP12
negatively regulates the hypoxia-inducible transcriptional activ-
ity of HIF-1 (Fig. 8A). AKAP12 also significantly downregulated
VEGF secretion, mRNA level, and transcriptional activity (Fig.
8B). Thus, these results strongly suggest that AKAP12 functions
as a negative regulator of HIF-1 and VEGF.
AKAP12 decreases the stability of HIF-1 by increasing its
association with pVHL
Overexpression of AKAP12 downregulated HIF-1 at the pro-
tein level but did not affect HIF-1 mRNA level (Fig. 7B,C),
suggesting that regulation of HIF-1 by AKAP12 was not result-
ing from reduced transcription of the gene encoding HIF-1.
Rather, our results indicate that the stability of the HIF-1 was re-
duced by AKAP12. We next examined whether AKAP12 plays a role
in the association of HIF-1 and pVHL, which leads to ubiquitina-
tion and degradation of HIF-1. Interestingly, the interaction of
HIF-1 and pVHL was potently increased by expression of AKAP12
and decreased by siAkap12 under both normoxic and hypoxic con-
ditions (Fig. 9A,B). Moreover, HIF-1 protein and mRNA levels
were unaffected, and VEGF mRNA level was also not changed by
AKAP12 in pVHL-deficient 786-O renal clear cell carcinoma cells
(Fig. 9C). In these cells, HIF-1 protein level was unaffected by
siAkap12 (Fig. 9D). In 786-O cells that stably expressed pVHL, how-
ever, HIF-1 protein level was upregulated after transfection of
Figure 5. AKAP12 regulates the expression of tight junction proteins, which is mediated by
Ang1. A, Expression of ZO-1, ZO-2, claudin-1, claudin-3, claudin-5, and occludin in HRMECs
treated with CM from Akap12-transfected astrocytes was analyzed by Western blot. M, Mock-
CM; A, AKAP12-CM; A/A, AKAP12-CM pretreated with anti-Ang1 antibody; A/I, AKAP12-CM
pretreated with control IgG. Representative Western blots are shown (n  3). B, RITC-dextran
passage was analyzed for vascular permeability in HRMECs at the same conditions as in A. *p 
0.01 compared with mock-CM; #p  0.01 compared with AKAP12-CM. C, Expression of ZO-1
and ZO-2 in HRMECs treated with 10 ng/ml VEGF165 and 100 ng/ml COMP-Ang1 for 6 h was
analyzed by Western blot (n  3). D, Top, Expression of ZO-1, ZO-2, and claudin-1 in HRMECs
treated with negative control or siAkap12-transfected CM (siAkap-CM) from astrocytes was
analyzed by immunofluorescence staining. Middle, The expression of claudin-5 and occludin
was analyzed by Western blot. Bottom, The quantification of the intensity from three indepen-
dent experiments is shown. The expression was set to 100% in CM from negative control-
transfected astrocytes. *p  0.05 compared with control; #p  0.001 compared with control.
Scale bar, 50 m.
Figure 6. HIF-1 is involved in the regulation of Ang1 expression. A, Human astrocytes were
transfected with siHIF-1, incubated for 12 h, then exposed to 24 h of normoxia or hypoxia.
HIF-1 in cell lysates, and Ang1 and VEGF in CM were analyzed by Western blot. The quantifi-
cation of the immunoblot from three independent experiments is shown on the right. Ang1
expression was set to 100% in siHIF-1-transfected hypoxic condition, and VEGF expression
was set to 100% in the control under hypoxia. *p  0.05 compared with control in normoxia;
**p  0.01 compared with control in normoxia; #p  0.05 compared with control in hypoxia;
##p  0.01 compared with control in hypoxia. -actin and Ponceau red staining served as the
controls for total protein levels. B, Astrocytes were transfected with siHIF-1, and mRNA levels
of HIF-1, Ang1, and VEGF were analyzed by RT-PCR.
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siAkap12 (Fig. 9D), indicating that the effect
of AKAP12 in HIF-1 downregulation is
pVHL-dependent.
AKAP12 decreases the stability of HIF-
1 by increasing its association
with PHD2
The VHL E3 ubiquitin ligase complex as-
sociates with hydroxylated proline resi-
dues and targets HIF-1 for proteasomal
degradation (Salceda and Caro, 1997;
Maxwell et al., 1999; Ivan et al., 2001;
Jaakkola et al., 2001). Because the silenc-
ing of PHD2 by transfection of siRNA is
sufficient to stabilize and activate HIF-1
under normoxic conditions in various hu-
man cells (Berra et al., 2003; Appelhoff et
al., 2004), we next investigated whether
the interaction of HIF-1 and PHD2 was
regulated by AKAP12. The interaction of
HIF-1 and PHD2 was potently increased
by expression of AKAP12, and decreased
by siAkap12, under both normoxic and
hypoxic conditions (Fig. 10A,B). Recov-
ery from AKAP12-induced destabilization
of HIF-1 was observed after transfection
of siRNA targeting PHD2 in astrocytes (Fig.
10C) and after treatment with the PHD in-
hibitors such as Mim or DHB in HT1080
cells (Fig. 10D). These results suggest that
AKAP12 is a key regulatory protein in the
degradation of HIF-1 through PHD2-
mediated proline hydroxylation and the
pVHL ubiquitination complex.
Discussion
In the present study, we investigated the
distribution of AKAP12, Ang1, VEGF, and
tight junction proteins in in vivo human
eye development (Fig. 1). We analyzed
immunostained retinas every week from
18 to 40 weeks of development. On still-
unvascularized retina, VEGF expression
was strongly detected (Figs. 1, 2A), which
may be caused by the increasing metabo-
lism of retinal neurons (Stone et al., 1995).
AKAP12 expression was clearly detected
from 23 to 40 weeks, and the staining pat-
tern was coincided spatiotemporally with
that of GFAP (Figs. 1, 2), suggesting that AKAP12 is expressed in
astrocytes. The highest expression of AKAP12, Ang1, and tight
junction proteins was detected from 26 to 34 weeks (Figs. 1, 2A),
which is the vascular maturation period in the human eye. Thus,
the expression of VEGF varied inversely with that of AKAP12,
because the VEGF-stained area remarkably decreased during BRB
maturation, whereas the areas stained by AKAP12, Ang1, and tight
junction proteins increased markedly.
Astrocytes play a key role in the development of retinal vessels
by detecting hypoxia in developing retina and by stimulating the
expression of hypoxia-induced angiogenic factors such as
HIF-1 and VEGF to induce new vessel formation (Stone et al.,
1995; Jain et al., 1998; Madan et al., 2002). Oxygen delivered by
the retinal vasculature is an important factor in the cessation of
retinal angiogenesis by downregulating HIF-1 protein (West et
al., 2005). Until recently, several posttranslational modifications
have been reported to regulate HIF-1 stability in the presence of
oxygen. A critical modification of HIF-1 involves prolyl hy-
droxylation, which targets HIF-1 to the pVHL ubiquitination
complex, leading to a rapid proteasomal degradation (Salceda
and Caro, 1997; Ivan et al., 2001). In contrast to HIF-1 protein
expression, the level of AKAP12 is increased in reoxygenated as-
trocytes (Fig. 7A). In our previous study, AKAP12/SSeCKS was
decreased by hypoxia, then strongly upregulated by reoxygen-
ation, as accessed by Western blot and RT-PCR (Lee et al., 2003),
indicating that AKAP12/SSeCKS expression was tightly regu-
lated, at least at the transcriptional level, in response to oxygen
tension. AKAP12 acts as a scaffold for multivalent signaling and
Figure 7. Negative regulation of HIF-1 by AKAP12. A, Human astrocytes were exposed to 24 h of normoxia (N) or hypoxia
(24H), or 24 h of hypoxia followed by reoxygenation for 3 h (3R). Expression of AKAP12 and HIF-1 was examined by Western blot
analysis. B, Human astrocytes were transfected with Akap12 (t-AKAP12), incubated for 12 h, then exposed to 24 h of normoxia or
hypoxia, and expression of HIF-1 was analyzed by Western blot. The quantification of the immunoblot from three independent
experiments is shown below. The expression under hypoxia was set to 100%. *p  0.05 compared with control in hypoxic
condition. C, Human astrocytes were transfected with Akap12, incubated for 12 h, then exposed to 24 h of normoxia or hypoxia,
and expression of HIF-1 was analyzed by RT-PCR. D, Human astrocytes were transfected with siAkap12, incubated for 12 h, then
exposed to 24 h of normoxia or hypoxia, and expression of AKAP12 and HIF-1 was analyzed by Western blot. -actin was used
as an internal control. The quantification of the immunoblot from four independent experiments is shown below. The expression
was set to 100% in siAkap12-transfected hypoxic condition. *p  0.05 compared with control in normoxic condition; #p  0.01
compared with control in hypoxic condition. E, HIF-1 (green) expression under the same set of normoxic condition was also
examined by immunofluorescence staining. Nuclei were stained with propidium iodide and are seen in red, and colocalization is
seen as yellow fluorescence. Scale bar, 50 m.
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associates with PKC, PKA, calmodulin, cyclins, F-actin, and
-adrenergic receptors, providing a dynamic, reversible platform
for signaling (Lin et al., 1996; Gelman, 2002). Recent reports
show that hypoxia/aglycemia alters expression and organization
of actin cytoskeletal protein, particularly mediated by phosphor-
ylation events by PKC or by calcium-regulated signaling (Park et
al., 1999; Brown et al., 2004; Brown and Davis, 2005). PKC-
induced phosphorylation of AKAP12 causes it to translocate
from cytoskeletal sites to the perinucleus in fibroblasts and mes-
angial and epithelial cells (Lin et al., 1996; Chapline et al., 1998;
Nelson et al., 1999). AKAP12 binding partners are also dynami-
cally recruited or released by these phosphorylation events
(Wong and Scott, 2004). Based on these reports, we assume that
hypoxic signaling may influence the expression or reorganization
of AKAP12 by inducing dynamic signal transduction. In this re-
port, we show that AKAP12 is an important negative regulator of
HIF-1 protein. Overexpression of AKAP12 diminished HIF-1
protein stability (Fig. 7B), whereas knockdown of AKAP12 by
siAkap12 significantly induced HIF-1 protein in normoxia (Fig.
7D,E). We demonstrated that AKAP12 induces HIF-1 degrada-
tion by upregulating HIF-1-pVHL and HIF-1-PHD2 interac-
tions (Figs. 9A, 10A).
Our findings suggest that AKAP12 mediates inner BRB matura-
tion by downregulating HIF-1 protein level, which leads to an in-
crease in the secretion of Ang1 and a decrease in the secretion of
VEGF in human astrocytes. In our previous study, the level of Ang1
was reduced in hypoxic condition and was increased in reoxygen-
ation condition in primary rat astrocyte cells (Song et al., 2002). In
this report, we investigated whether HIF-1 is involved in the regu-
lation of Ang1 expression, and found that HIF-1 can act as a neg-
ative regulator of Ang1 because diminished HIF-1 level by
siHIF-1 increased the expression of Ang1 in CM (Fig. 6A). Inter-
Figure 8. Regulation of transcriptional activities of HIF-1 and VEGF by AKAP12. A, For
analysis of HIF-1 transcriptional activity, cells were transfected with pSV40pro-EpoHRE-Luc (1
g) or mutated EpoHRE-Luc (1 g), pBOS-HIF-1 (0.1 g), pBOS-HIF-1 (0.1 g), or empty
vector (pEF-BOS, 0.2 g), pCMV--gal (0.5 g), and 2 g of pcDNA3-Akap12 or pcDNA3, as
indicated. Transfected cells were incubated for 12 h, then exposed to 24 h of normoxia or
hypoxia. B, Cells were transfected with Akap12, incubated for 12 h, then exposed to 24 h of
normoxia or hypoxia. VEGF expression was analyzed by Western blot analysis of CM (100 g
total protein) and RT-PCR. For analysis of VEGF transcriptional activity, cells were transfected with
pcDNA-Akap12 or pcDNA (2 g), the VEGF promoter vector pGL3-mVEGF (1 g), pBOS-HIF-1 (0.1
g), pBOS-HIF-1 (0.1 g), or empty vector (pEF-BOS; 0.2 g), and pCMV--gal (0.5 g). After
transfection, cells were incubated for 12 h and then exposed to 24 h normoxia or hypoxia.
Figure 9. AKAP12 decreases the stability of HIF-1 by increasing its association with pVHL.
A, B, Human astrocytes were transfected with AKAP12 or siAkap12, incubated for 12 h, and then
exposed to 24 h of normoxia or hypoxia. Cells were treated with 8 M MG132 for 4 h and then
cell extracts were subjected to immunoprecipitation using anti-pVHL antibody. Immunopre-
cipitates were analyzed by Western blot using anti-HIF-1 antibody (A). The quantification of
the immunoblot from three independent experiments is shown (B). *p  0.05 compared with
control in normoxic condition. C, 786-O renal clear cell carcinoma cells were transfected with
Akap12 (1.5 g) and green fluorescent protein (GFP)-HIF-1 (1.5 g). The expression of
HIF-1 was analyzed by Western blot and RT-PCR. D, 786-O cells and 786-O cells expressing
pVHL (786-O cell/pVHL) were transfected with siAkap12 and GFP-HIF-1 (1.5 g), incubated
for 12 h, then exposed to 24 h of normoxia or hypoxia, and expression of HIF-1 and pVHL was
analyzed by Western blot. The quantification of the immunoblot from three independent ex-
periments is shown below. *p  0.05 compared with control in normoxic condition.
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estingly, the 5UTR region of human Ang1 contains three potential
reverse HRE (rHRE) regions (DNA consensus 5-TGCAC-3). A
recent study showed that HIF-1 acts as a transcriptional repressor
of certain genes by direct binding to specific rHREs, HREs on the
antisense strand (Narravula and Colgan, 2001). These could provide
the possibility of the downregulation of Ang1 level by HIF-1. Based
on this assumption, it will be interesting to explore the mechanisms
of how HIF-1 regulates Ang1 level.
AKAP12 significantly regulates the secretion levels of Ang1
and VEGF (Fig. 4B,C) more than the intracellular Ang1 and
VEGF levels (data not shown) because the BRB formation re-
quires the binding of secreted Ang1 and VEGF to endothelial cell
receptors (Millauer et al., 1993; Davis et al., 1996). VEGF is the
principal factor involved in retinal angiogenesis (Dvorak et al.,
1999; Provis, 2001) and in the breakdown of the BRB (Qaum et
al., 2001; Wang et al., 2001; Witmer et al., 2003). However, Ang1
acts in human retinal vessel development, namely, during vessel
remodeling, maturation, and stabilization (Thurston et al., 2000;
Joussen et al., 2002). Transgenic mice with inducible expression
of Ang1 in the retina decreased VEGF-induced leakiness of the
vessels (Nambu et al., 2004). Thus, AKAP12 may reciprocally
regulate the secretion of Ang1 and VEGF through HIF-1 in
astrocytes during a critical period in human retinal vascular mat-
uration and contribute to BRB development by upregulating the
expression of tight junction proteins ZO-1, ZO-2, claudin-1,
claudin-3, claudin-5, and occludin in endothelial cells (Fig. 5A).
In contrast to its expression during inner BRB development,
AKAP12 expression was absent in retinoblastoma tissues (Figs. 1,
3B). Notably, whereas VEGF immunoreactivity in the mature
normal retina was negligible (Figs. 1, 2A), it was strongly detected
in retinoblastoma tissue (Fig. 3B). These results corroborate
studies showing a marked increase in VEGF expression in eyes
bearing intraocular tumors (Stitt et al., 1998). Therefore, the ex-
tremely reduced expression of AKAP12 in retinoblastoma may
lead to upregulation of HIF-1 and VEGF, which can then induce
the BRB breakdown associated with these tumors.
In conclusion, we show that AKAP12 plays a critical role in me-
diating important interactions between retinal endothelial cells and
astrocytes during human retinal barriergenesis. These observations
provide insight into normal retinal barrier development, and the
retinal diseases associated with barrier defects, such as retinoblas-
toma, diabetic retinopathy, and retinopathy of prematurity.
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